Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Anthropic Signs $9.1B AI Data Center Deal With Riot Platforms 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
US Judge Dismisses Gautam Adani Criminal Charges 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
A US district court upheld the validity of Novartis' patent for its top-selling multiple sclerosis (MS) drug Gilenya, rejecting a lawsuit from generic drug maker HEC.
Gilenya is the Swiss drugmaker's No. 2 revenue generator at $738 million in the second quarter.
HEC had sought approval to make a generic copy of Gilenya before the expiration of Novartis' patent with the US Food and Drug Administration (FDA).
The Swiss drugmaker said it continued the injunction against the marketing and sale of Gilenya and other generics granted to it in June 2019.
The FDA approved three generic versions of the Novartis MS treatment in December.
Novartis had settlement agreements with other manufacturers to allow them to launch generic versions of Gilenya before the patent expires in 2027.
